Lung cancer
Cancer
|
Breast guidelines test American tolerance for risk...about getting yearly mammograms. "We're emotional because we're so damn confused," Ryan said. Dr. Kyle Hogarth, who directs a lung cancer risk clinic at the University of Chicago School of Medicine, said there are no official... In this article: Breast cancer, Lung cancer, Nodule, Burden of proof, University of Chicago School of Medicine, Cancer, and University of Alabama at Birmingham |
-
scotsman.com - Scotland | 3 days ago
Errors with X-rays led to delays in lung cancer diagnosis
To read this article in full you must be registered with the site. Published Date: 19 November 2009 THE diagnosis of two patients with lung cancer was delayed after mistakes in checking X-rays, a report found yesterday. Overall, a...
In this article: Barium, Royal College of Radiologists, and Ireland
-
Prime Newswire | 4 days ago
OXiGENE Reports Positive Safety Data From Phase 2 Trial of ZYBRESTAT in Non-Small Cell Lung Cancer at the 2009 AACR-NCI-EORTC Conference
...ZYBRESTAT is an active antitumor agent, and we are encouraged by the data presented today in patients with advanced non-small cell lung cancer," commented Peter Langecker, M.D., Ph. D., OXiGENE's Chief Executive Officer. "OXiGENE's FALCON study...
In this article: Bevacizumab, Carboplatin, Cancer, Paclitaxel, Platinum, Anaplastic thyroid cancer, and Ovarian cancer
-
Medical News Today | 4 days ago
ASCO Releases Updated Treatment Guidelines For Patients With Stage 4 Non-Small Cell Lung Cancer
...to help physicians and patients have a better dialogue on the potential benefits, risks, and prognosis of treating stage 4 non-small cell lung cancer with chemotherapy, as well as a slide presentation and a summary in the Journal of Oncology...
In this article: Cancer, Gefitinib, Erlotinib, Pemetrexed, Carboplatin, Paclitaxel, Irinotecan, and Gemcitabine
-
Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Of Picoplatin In Small Cell Lung Cancer Did Not Meet Primary Endpoint
...its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in the second-line treatment of small cell lung cancer (SCLC) did not meet its primary endpoint of overall survival. The analysis, based on 320...
In this article: Cancer, Platinum, FDA, Medical advice, National Comprehensive Cancer Network, and Nasdaq
-
AP Online | 5 days ago
Poniard cancer drug misses goal in lung cancer
...its shares plunging in early trading. Poniard was running a late-stage trial of picoplatin as a secondary treatment for non-small cell lung cancer, meaning the drug was given to patients who had previously been treated for the disease and...
In this article: Cancer and Food and Drug Administration
-
L.A. Times - Booster Shots | November 13, 2009
Rodent of the Week: Drug shows effect on lung cancer tumors
...has found a promising drug that may enter clinical trials in humans within a year. One in five people with lung cancer has small-cell lung cancer. The disease has a poor long-term survival rate because the tumors spread quickly. Previous...
In this article: Fgf-2, Growth hormone, Cancer Research, Imperial College London, Small-cell lung cancer, Advanced Cell Technology, Los Angeles Times, and Los Angeles
-
Independent.ie | November 11, 2009
Deadliest lung cancer breakthrough
...these tumours completely disappear." One in five lung cancer sufferers have a particularly virulent strain called small cell lung cancer which kills all but three per cent of sufferers within five years of diagnoses. With this form of...
In this article: Cancer, Cancer Research, Imperial College London, and Cancer Research UK
-
BBC News | November 10, 2009
Drug 'shrinks lung cancer tumour'
Scientists have identified a drug which may offer hope to patients with a particularly lethal form of lung cancer. The drug eliminated small cell lung cancer tumours in 50% of mice, and blocked the cells' ability to resist standard...
In this article: Fgf-2, Imperial College London, Growth hormone, Cancer Research, Surgery, Cisplatin, Cancer, and Cancer Research UK
Trends
Loading...
More on Lung cancer
Description from Wikipedia:
Lung cancer is a disease of uncontrolled cell growth in tissues of the lung. This growth may lead to metastasis, invasion of adjacent tissue and infiltration beyond the lungs. The vast majority of primary lung cancers are carcinomas of the lung, derived from epithelial cells. Lung cancer, the most common cause of cancer-related death in men and the second most common in women, is responsible for 1.3 million deaths worldwide
annually. The most common symptoms are shortness of breath, coughing (including coughing up blood), and weight loss.
The main types of lung cancer are small cell lung carcinoma and non-small cell lung carcinoma. This distinction is important because the treatment varies; non-small cell lung carcinoma (NSCLC) is sometimes treated with surgery, while small cell lung carcinoma (SCLC) usually responds better to chemotherapy and radiation. The most common cause of lung cancer is long term exposure to tobacco smoke. The occurrence of lung cancer in non-smokers, who account for as many as 20% of cases, is often attributed to a combination of genetic factors, radon gas, asbestos, and air pollution, including second-hand smoke.
Lung cancer may be seen on chest x-ray and computed tomography (CT scan). The diagnosis is confirmed with a biopsy. This is usually performed via bronchoscopy or CT-guided biopsy. Treatment and prognosis depend upon the histological type of cancer, the stage (degree of spread), and the patient's performance status. Possible treatments include surgery, chemotherapy, and radiotherapy. With treatment, the five-year survival rate is 14%.
Explore everything named Lung cancer...
